Receptor binding and internalization of a water-soluble (1→3)-β-D-glucan biologic response modifier in two monocyte/macrophage cell lines

Journal of Immunology

Volumn 156, Issue 9, 1996, Pages 3418-3425

  Müller, Antje ^a   Rice, Peter J ^a   Ensley, Harry E ^b   Coogan, Philip S ^a   Kalbfleisch, John H ^a   Kelley, Jim L ^a   Love, Edward J ^a   Portera, Charles A ^a   Ha, Tuanzhu ^a   Browder, I William ^a,c   Williams, David L ^a,c  

^a East Tennessee State University   (United States)

^b Tulane University   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; BIOLOGICAL RESPONSE MODIFIER; GLUCAN PHOSPHATE; POLYSACCHARIDE; PULLULAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CELL VACUOLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTERNALIZATION; MACROPHAGE; MITOSIS; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; BETA-GLUCANS; BINDING SITES; BINDING, COMPETITIVE; BIOLOGICAL RESPONSE MODIFIERS; CELL LINE; GLUCANS; HUMANS; LYMPHOMA, LARGE-CELL; MACROPHAGES; MICE; MONOCYTES; RECEPTORS, IMMUNOLOGIC; SOLUBILITY;

EID: 0029916578     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Sasaki, T., and N. Takasuka. 1976. Further study of the structure of lentinan, an anti-tumor polysaccharide from lentinus edodes. Carbohydr. Res. 47:99.
2. Bluhm, T. L., Y. Deslandes, R. H. Marchessault, S. Perez, and M. Rinaudo. 1982. Solid-state and solution conformation of scleroglucan. Carbohydr. Res. 100:117.
3. Tabata, K., W. Ito, T. Kojima, S. Kawabata, and A. Misaki. 1981. Ultrasonic degradation of schizophyllan, an antitumor polysaccharide produced by schizophyllum commune fries. Carbohydr. Res. 89:121.
4. Ensley, H. E., B. Tobias, H. A. Pretus, R. B. McNamee, E. L. Jones, I. W. Browder, and D. L. Williams. 1994. NMR spectral analysis of a water insoluble (1→3)-β-D-glucan isolated from Saccharomyces cerevisiae. Carbohydr. Res. 258:307.
5. Sherwood, E. R., D. L. Williams, R. B. McNamee, E. L. Jones, I. W. Browder, and N. R. DiLuzio. 1987. Enhancement of interleukin-1 and interleukin-2 production by soluble glucan. Int. J. Immunopharmacol. 9:261.
6. Williams, D. L., I. W. Browder, and N. R. DiLuzio. 1983. Immunotherapeutic modification of Escherichia coli-induced experimental peritonitis and bacteremia by glucan. Surgery 93:448.
7. Browder, W., D. Williams, E. Sherwood, R. McNamee, E. Jones, and N. DiLuzio. 1987. Synergistic effect of nonspecific immunostimulation and antibiotics in experimental peritonitis. Surgery 102:206.
8. Rasmussen, L. T., P. E. Lipsky, and R. Seljelid. 1987. Production of prostaglandin E2 and interleukin 1 by mouse peritoneal macrophages stimulated with beta-1,3-D-glucan derivatized plastic beads. Scand. J. Immunol. 26:731.
9. Browder, W., D. Williams, H. Pretus, G. Olivero, F. Enrichens, P. Mao, and A. Franchello. 1990. Beneficial effect of enhanced macrophage function in the trauma patient. Ann. Surg. 211:605.
10. Felippe, J., M. Silva, F. M. Maciel, A. Soares, and N. F. Mendes. 1993. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surg. Gynecol. Obstet 177:383.
11. Babineau, T. J., P. Marcello, W. Swails, A. Kenler, B. Bistrian, and R. A. Forse. 1994. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann. Surg. 220:601.
12. Babineau, T. J., A. Hackford, A. Kenler, B. Bistrian, R. A. Forse, P. G. Fairchild, S. Heard, M. Keroack, P. Causha, and P. Benotti. 1994. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (pgg-glucan) in high-risk surgical patients. Arch. Surg. 129:1204.
13. Browder, W., D. Williams, P. Lucore, H. Pretus, E. Jones, and R. McNamee. 1988. Effect of enhanced macrophage function on early wound healing. Surgery 104:224.
14. Sherwood, E. R., D. L. Williams, and N. R. Di Luzio. 1986. Glucan stimulates production of antitumor cytolytic/cytostatic factor(s) by macrophages. J. Biol. Response Modif. 5:504.
15. Daum, T., and M. S. Rohrbach. 1992. Zymosan induces selective release of arachidonic acid from rabbit alveolar macrophages via stimulation of a β-glucan receptor. FEBS 309:119.
16. Konopski, Z., L.-T. Rasmussen, R. Seljelid, and T. Eskeland. 1991. Phagocytosis of β-1,3-D-glucan derivatized microbeads by mouse peritoneal macrophages involves three different receptors. Scand. J. Immunol. 33:297.
17. Ross, G. D., J. A. Cain, B. L. Myones, S. L. Newman, and P. J. Lachmann. 1987. Specificity of membrane complement receptor type three (CR3) for β-glucans. Complement 4:61.
18. Ross, G. D., J. A. Cain, and P. J. Lachmann. 1985. Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin and functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3bl. J. Immunol. 134:3307.
19. Elstad, M. R., C. J. Parker, F. S. Cowley, L. A. Wilcox, T. M. McIntyre, S. M. Prescott, and G. A. Zimmerman. 1994. CD11b/CD18 integrin and a β-glucan receptor act in concert to induce the synthesis of platelet-activating factor by monocytes. J. Immunol. 152:220.
20. Konopski, Z., B. Smedsrod, R. Seljelid, and T. Eskeland. 1994. A novel immunomodulator soluble aminated β-1,3-D-glucan: binding characteristics to mouse peritoneal macrophages. Biochim. Biophys. Acta 1221:61.
21. Tapper, H., and R. Sundler. 1995. Glucan receptor and zymosan-induced lysosomal enzyme secretion in macrophages. J. Biochem. 306:829.
22. Duan, X., M. Ackerly, E. Vivier, and P. Anderson. 1994. Evidence for involvement of beta-glucan-binding cell surface lectins in human natural killer cell function. Cell. Immunol. 157:393.
23. Muller, C. D., V. Bocchini, J. Giaimis, P. Guerrieri, Y. Lombard, and P. Poindron. 1994. Functional β-glucan receptor expression by a microglial cell line. Res. Immunol. 145:267.
24. Goldman, R., E. Ferber, R. Meller, and U. Zor. 1994. A role for reactive oxygen species in zymosan and β-glucan induced protein tyrosine phosphorylation and phospholipase A2 activation in murine macrophages. Biochim. Biophys. Acta 1222:265.
25. Sanguedolce, M., C. Capo, M. Bouhamdan, P. Bongrand, C. Huang, and J. Mege. 1993. Zymosan-induced tyrosine phosphorylations in human monocytes. J. Immunol. 151:405.
26. Hoffman, O. A., E. J. Olson, and A. H. Limper. 1993. Fungal β-glucans modulate macrophage release of tumor necrosis factor-α in response to bacterial lipopolysaccharide. Immunol. Lett. 37:19.
27. Konopski, Z., R. Seljelid, and T. Eskeland. 1994. IFN-gamma inhibits internalization of soluble aminated β-1,3-D-glucan by macrophages and thereby down-regulates the glucan induced release of TNF-α and IL-1β. Scand. J. Immunol. 40:57.
28. Au, B., T. J. Williams, and P. D. Collins. 1994. Zymosan-induced IL-8 release from human neutrophils involves activation via the CD11b/CD18 receptor and endogenous platelet-activating factor as an autocrine modulator. J. Immunol. 152: 5411.
29. Abel, G., and J. K. Czop. 1992. Stimulation of human monocyte β-glucan receptors by glucan particles induces production of TNF-α and IL-1β. Immunopharmacology 14:1363.
30. Czop, J. K., and K. F. Austen. 1985. Beta-glucan inhibitable receptor on human monoyctes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. J. Immunol. 134:2588.
31. Czop, J. K., and K. F. Austen. 1985. Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor. J. Immunol. 135:3388.
32. Czop, J. K., and J. Kay. 1991. Isolation and characterization of β-glucan receptors on human mononuclear phagocytes. J. Exp. Med. 173:1511.
33. Williams, J. D., N. Topley, H. M. Alobaidi, and M. J. Barber. 1986. Activation of human polymorphonuclear leucocytes by particulate zymosan is related to both its major carbohydrate components: glucan and mannan. Immunology 58:117.
34. 3. Immunology 63:319.
35. Goldman, R. 1988. Characteristics of the beta-glucan receptor of murine macrophages. Exp. Cell Res. 174:481.
36. Janusz, M. J., K. F. Austen, and J. K. Czop. 1989. Isolation of a yeast heptaglucoside for monocyte phagocytic β-glucan receptors. FASEB J. 3:6421.
37. Janusz, M. J., K. F. Austen, and J. K. Czop. 1989. Isolation of a yeast heptaglucoside that inhibits monocyte phagocytosis of zymosan particles. J. Immunol. 142:959.
38. Czop, J., M. Gurish, and J. Kadish. 1990. Production and isolation of rabbit anti-idiotypic antibodies directed against the human monocyte receptor for yeast β-glucans. J. Immunol. 135:995.
39. Szabo, T., J. L. Kadish, and J. K. Czop. 1995. Biochemical properties of the ligand-binding 20-kDa subunit of the β-glucan receptors on human mononuclear phagocytes. J. Biol. Chem. 270:2145.
40. Konopski, Z., J. Fandrem, R. Seljedid, and T. Eskeland. 1995. Interferon-γ inhibits endocytosis of soluble animated β-1,3-D-glucan and neutral red in mouse peritoneal macrophages. J. Interferon Cytokine Res. 15:597.
41. Lombard, Y., J. Giaimis, M. Makaya-Kumba, P. Fonteneau, and P. Poindron. 1994. A new method for studying the binding and ingestion of zymosan particles by macrophages. J. Immunol. Methods 174:155.
42. Gallin, E. K., S. W. Green, and M. L. Patchen. 1992. Comparative effects of particulate and soluble gucan on macrophages of C3H/Hen and C3H/HeJ mice. Int. J. Immunopharmacol. 14:173.
43. Williams, D. L., R. B. McNamee, E. L. Jones, H. A. Pretus, H. E. Ensley, I. W. Browder, and N. R. Di Luzio. 1991. A method for the solubilization of a (1-3)-β-D-glucan isolated from Saccharomyces cerevisiae. Carbohydr. Res. 219:203.
44. Williams, D. L., E. R. Sherwood, I. W. Browder, R. B. McNamee, E. L. Jones, and N. R. Di Luzio. 1988. Pre-clinical safety evaluation of soluble glucan. Int. J. Immunopharmacol. 10:405.
45. Pretus, H. A., H. E. Ensley, R. B. McNamee, E. L. Jones, I. W. Browder, and D. L. Williams. 1991. Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan. J. Pharmacol. Exp. Ther. 257:500.
46. Mueller, A., H. Pretus, R. McNamee, E. Jones, I. Browder, and D. Williams. 1995. Comparison of the carbohydrate biological response modifiers krestin, schizophyllan and glucan phosphate by aqueous size exclusion chromatographty with in-line argon-ion multi-angle laser light scattering photometry and differential viscometry detectors. J. Chromatogr. 666:283.
47. Williams, D. L., H. A. Pretus, and I. W. Browder. 1992. Application of aqueous gel permeation chromatography with in-line multi-angle laser light scattering and differential viscometry detectors for the characterization of natural product carbohydrate pharmaceuticals. J. Liquid Chromatogr. 15:2297.
48. Takasaki, S., and A. Kobata. 1978. Microdetermination of sugar composition by radioisotope labeling. Methods Enzymol. 50:50.
49. Schmidt, W. E., and J. Ebel. 1987. Specific binding of a fungal glucan phytoalexin elicitor to membrane fractions from soybean glycine max. Proc. Natl. Acad. Sci. USA 84:4117.
50. Sundstroem, C., and K. Nilsson. 1976. Establishment and characterization of a human histiocytic lymphoma cell line. Int. J. Cancer 17:565.
51. Ralph, P., and I. Nakoinz. 1977. Direct toxic effects of immunopotentiators on monocytic, myelomonocytic, and histiocytic or macrophage tumor cells in culture. Cancer Res. 37:546.
52. Kawahara, K., K. Ohta, H. Miyamoto, and S. Nakamura. 1984. Preparation and solution properties of pullulan fractions as standard samples for water-soluble polymers. Carbohydr. Polymers 4:335.
53. Poutsiaka, D. D., M. Mengozzi, E. Vannier, B. Sinha, and C. A. Dinarello. 1993. Cross-linking of the beta-glucan receptor on human monocytes results in interleukin-1 receptor antagonist but not interleukin-1 production. Blood 82:3695.
54. Williams, D., A. Mueller, and W. Browder. 1995. Preclinical and clinical evaluation of carbohydrate immunopharmaceuticals in the prevention of sepsis and septic sequelae. J. Endotoxin Res. 2:203.
55. Yanaki, T., W. Ito, K. Tabata, T. Kojima, T. Norisuye, N. Takano, and H. Fujita. 1983. Correlation between the antitumor activity of a polysaccharide schizophyllan and its triple-helical conformation in dilute aqueous solution. Biophys. Chem. 17:337.
56. Tanaka, S., J. Aketagawa, S. Takahashi, and Y. Shibata. 1991. Activation of a limulus coagulation factor G by (1→3)-β-glucans. Carbohydr. Res. 218:167.
57. Ohya, Y., T. Nishmioto, J. Murata, and T. Ouchi. 1994. Immunological enhancement activity of muramyl dipeptide analogue/CM-curdlan conjugate. Carbohydr. Polymers 23:47.
58. Kishida, E., Y. Sone, and A. Misaki. 1992. Effects of branch distribution and chemical modifications of antitumor (1→3)-β-D-glucans. Carbohydr. Polymers 17:89.
59. Saito, H., Y. Yoshioka, N. Uehara, J. Aketagawa, S. Tanaka, and Y. Shibata. 1991. Relationship between conformation and biological response for (1→3)-β-D-glucans in the activation of coagulation factor G from limulus amebocyte lysate and host-mediated antitumor activity: demonstration of single-helix conformation as a stimulant. Carbohydr. Res. 217:181.
60. Deckers, H. A., C. Olieman, F. M. Rombouts, and W. Pilnik. 1986. Calibration and application of high-performance size exclusion columns for molecular weight distribution of pectins. Carbohydr. Polymers 6:361.
61. Hirai, R., Y. Oguchi, N. Sugita, K. Matsunaga, and K. Nomoto. 1993. Short communication enhancement of T-cell proliferation by PSK. Int. J. Immunopharmacol. 15:745.
62. Wyatt, P. J. 1993. Light scattering and the absolute characterization of macromolecules. Anal. Chim. Acta 272:1.
63. Duvic, B., and K. Söderhäll. 1990. Purification and characterization of a β-1,3-glucan binding protein from plasma of the crayfish Pacifastacus leniusculus. J. Biol. Chem. 265:9327.
64. Cosio, E. G., H. Poepperl, W. E. Schmidt, and J. Ebel. 1988. High-affinity binding of fungal β-glucan fragments to soybean (glycine max L.) microsomal fractions and protoplasts. Eur. J. Biochem. 175:309.
65. Van Strijp, J. A. G., D. Russell, E. Tuomanen, E. Brown, and S. Wright. 1993. Ligand specificity of purified complement receptor type three. J. Immunol. 151: 3324.